Workflow
健康消费品
icon
Search documents
深圳创新药械不断加速 重点布局四大新兴赛道
Market Overview - The Chinese medical equipment market is projected to reach 1.35 trillion yuan in 2024, with an average growth rate exceeding 12% over the past decade, making it the second-largest market globally [2][6] - Shenzhen's pharmaceutical and medical device industry is expected to achieve a production value of 157.6 billion yuan in 2024, with medical devices alone surpassing 102.8 billion yuan, maintaining its position as the leading region in China for ten consecutive years [3] Industry Innovation - China is increasingly focusing on quality improvements in its medical equipment sector, with one-third of global medical equipment patents originating from the country, indicating a strengthening of domestic innovation capabilities [2][6] - Shenzhen has nurtured 35 listed companies in the pharmaceutical and medical device sectors, along with over 1,000 enterprises above designated size, showcasing a robust industrial ecosystem [3] Recent Developments - Notable recent collaborations include a 47 billion HKD (approximately 5.99 billion USD) partnership between Crystal Technology and DoveTree for AI drug development, marking a significant milestone in the commercialization of AI in pharmaceuticals [4] - Health元's innovative drug, Marpacisavir capsules, has received approval for market launch, representing a breakthrough in flu treatment with a unique mechanism requiring only one oral dose [5] Future Directions - Shenzhen aims to focus on four emerging sectors: cell and gene therapy, biomanufacturing, AI in pharmaceuticals, and health consumer products, to enhance its competitive edge in the medical equipment industry [6][7] - The establishment of an "AI + Biomanufacturing Public Service Platform" is set to accelerate the R&D cycle for biomanufacturing companies, significantly reducing development time from years to months [7]